Parkinson’s disease affects over 8.5 million people worldwide, making it the second most common neurodegenerative condition after Alzheimer’s. In the United States alone, estimates range from 500,000 to 1 million people living with the disease, though the true number is likely higher because many cases go undiagnosed or are misdiagnosed.
Prevalence by Age
Parkinson’s is overwhelmingly a disease of aging. Risk rises sharply after 60, and people over 80 have the highest rates of any age group. A 2024 modeling study in The BMJ projected that by 2050, roughly 1 in 50 people over 80 will be living with Parkinson’s, and the total number of cases in that age group will nearly triple compared to 2021.
When symptoms appear before age 50, it’s classified as young-onset Parkinson’s disease. A much rarer form, sometimes called juvenile Parkinson’s, develops before age 21. While these younger cases get significant media attention, they represent a small fraction of the total. The vast majority of diagnoses happen between ages 60 and 80.
Men Are Diagnosed More Often Than Women
Men develop Parkinson’s about 1.5 times more often than women overall, and this gap widens with age. Below 50, rates are roughly equal between men and women. But after 80, men are nearly twice as likely to be diagnosed. A meta-analysis of 22 studies covering more than 14,000 cases confirmed this pattern: the male-to-female ratio climbs steadily with each decade of life.
The reasons aren’t fully understood, but several factors likely contribute. Estrogen appears to have a protective effect on the brain cells that Parkinson’s damages. Women who had their ovaries surgically removed, for instance, face a higher risk of developing the condition. Men also tend to have higher lifetime exposure to chemicals like pesticides and industrial solvents, which are linked to increased risk. There are also structural differences in how the brain’s dopamine system is built between the sexes, which may make men inherently more vulnerable.
Many Cases Are Misdiagnosed
One reason Parkinson’s prevalence is hard to pin down is that diagnosis remains surprisingly inaccurate. A meta-analysis published in Neurology found that only about 8 out of 10 patients with Parkinson’s-like symptoms receive a correct diagnosis. When the diagnosis was made by a general neurologist or primary care doctor rather than a movement disorder specialist, accuracy dropped to around 74%. Even specialists at major medical centers got it right only about 80% of the time on initial assessment, improving modestly to 84% after follow-up visits.
There’s no blood test or brain scan that definitively confirms Parkinson’s. Diagnosis relies on clinical observation of symptoms like tremor, stiffness, and slowness of movement, which overlap with several other conditions. The National Institute of Neurological Disorders and Stroke notes that many individuals go undiagnosed entirely, meaning the real number of people living with Parkinson’s is almost certainly higher than official counts suggest.
Cases Are Rising Fast
Parkinson’s is one of the fastest-growing neurological conditions in the world, driven primarily by aging populations. The BMJ modeling study projected that among people over 80, the number of cases will increase by roughly 196% between 2021 and 2050. This growth pattern holds across all regions, from high-income countries to the developing world.
Population aging isn’t the only factor. People are living longer with chronic conditions, and diagnostic awareness has improved, meaning more cases are caught that would have been missed in previous decades. Some researchers also suspect rising environmental exposures to pesticides and industrial chemicals are contributing, though separating this signal from better detection is difficult.
The Financial Weight of Parkinson’s
The cost of Parkinson’s in the United States reached $82.2 billion in 2024, surpassing earlier projections. Of that, $23.8 billion went to direct medical expenses like hospitalizations, outpatient visits, and medications. The remaining $58.4 billion came from indirect costs: lost income, disability payments, and the enormous burden of unpaid caregiving by family members.
Costs begin piling up well before a diagnosis is confirmed. Patients incurred an average of more than $10,000 in additional medical costs in the year before diagnosis alone, reflecting the long and often uncertain path to getting answers. As the disease progresses, care needs intensify, and many patients eventually require full-time assistance with daily activities.
Mortality Across the U.S.
Parkinson’s itself doesn’t kill directly in most cases, but it contributes to death through complications like falls, pneumonia, and difficulty swallowing. CDC data from 2024 shows age-adjusted mortality rates ranging from about 6 deaths per 100,000 people in New York to over 13 per 100,000 in Utah. Most states cluster between 9 and 11 per 100,000. The variation likely reflects differences in population demographics, diagnostic practices, and how death certificates are completed rather than dramatic differences in disease risk from state to state.